To the full analysis
Mesa Laboratories stock: growth
MLABMesa Laboratories reported $249.13M in revenue for fiscal 2026, up 3.4% on the prior year, up 13.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.1%
per year from 2007 to 2026, per share 11.8%
Earnings (Annual rate)
2.8%
per year from 2007 to 2026, per share −0.1%
Free cash flow (Annual rate)
16.3%
per year from 2007 to 2026, per share 12.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 13.2% | 11.4% | 15.1% |
| Revenue per share | 10.9% | 6.8% | 11.8% |
| Earnings | 15.4% | −5.0% | 2.8% |
| Earnings per share | 13.1% | −8.9% | −0.1% |
| Free cash flow | 2.4% | 15.7% | 16.3% |
| Free cash flow per share | 0.4% | 10.9% | 12.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $17.24M | $3.96M | $2.25M |
| 2008 | $19.56M | $4.61M | $4.26M |
| 2009 | $21.54M | $4.79M | $4.4M |
| 2010 | $21.93M | $4.77M | $2.82M |
| 2011 | $32.83M | $6.18M | $6.23M |
| 2012 | $39.62M | $7.92M | $11.81M |
| 2013 | $46.44M | $8.45M | $10.49M |
| 2014 | $52.72M | $9M | $11.33M |
| 2015 | $71.33M | $9.58M | $7.99M |
| 2016 | $84.66M | $11.17M | $9.17M |
| 2017 | $93.67M | $11.18M | −$3.86M |
| 2018 | $96.18M | −$2.96M | $22.02M |
| 2019 | $103.14M | $7.48M | $29.29M |
| 2020 | $117.69M | $1.78M | $25.06M |
| 2021 | $133.94M | $3.27M | $35.08M |
| 2022 | $184.34M | $1.87M | $34.79M |
| 2023 | $219.08M | $930K | $23.44M |
| 2024 | $216.19M | −$254.25M | $41.57M |
| 2025 | $240.98M | −$1.97M | $42.31M |
| 2026 | $249.13M | $6.71M | $39.58M |
Revenue by segment
How Mesa Laboratories, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Sterilization and Disinfection Control$101.6M41%
- Calibration Solutions$53.6M21%
- Biopharmaceutical Development$48.6M20%
- Clinical Genomics$45.4M18%
The company split earlier years differently. A history would not be comparable, so only 2026 is shown.
Figures as a table
| 2026 | Share 2026 | |
|---|---|---|
| Sterilization and Disinfection Control | $101.57M | 40.8% |
| Calibration Solutions | $53.55M | 21.5% |
| Biopharmaceutical Development | $48.63M | 19.5% |
| Clinical Genomics | $45.39M | 18.2% |
| Total revenue | $249.13M | 100% |
Revenue by region
Where Mesa Laboratories, Inc. generates its revenue.
- United States47%
- China8%
- Other45%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2023 | 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|---|
| United States | $117.28M | $106.4M | $116.62M | $116.9M | 46.9% |
| China | $25.8M | $24.93M | $25.31M | $20.45M | 8.2% |
| Other | $76M | $84.86M | $99.05M | $111.79M | 44.9% |
| Total revenue | $219.08M | $216.19M | $240.98M | $249.13M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.